Don't miss

Replay


LATEST SHOWS

THE DEBATE

Colombia's Path to Peace: Can historic deal with FARC rebels work? (part 1)

Read more

THE DEBATE

Colombia's Path to Peace: Can historic deal with FARC rebels work? (part 2)

Read more

FOCUS

The rise of political tourism in the Middle East

Read more

ENCORE!

Music show: Video Music Awards, Rock en Seine and Puppa Lek Sen

Read more

YOU ARE HERE

The Gulf of Porto, a paradise of land and sea

Read more

IN THE PAPERS

Quarterback takes a stand by sitting down

Read more

FRANCE IN FOCUS

The hidden secrets of Les Invalides

Read more

IN THE PAPERS

Anger over restaurant's decision to deny service to Muslim women

Read more

BUSINESS DAILY

Fed rate hints show Brexit 'not a shock' for US economy

Read more

SCIENCE

Teenage girl dies after receiving cervical cancer vaccine

Text by NEWS WIRES

Latest update : 2009-09-29

A 14-year-old British girl died on Monday shortly after receiving a cervical cancer vaccine made by GlaxoSmithKline. A link between the death and the drug has not yet been established, health officials said on Monday.

REUTERS - A teenage British girl died after receiving a cervical cancer vaccine made by GlaxoSmithKline, but a link between the death and the drug has not yet been established, health officials said on Monday.

The 14-year-old fell ill after she was given the Cervarix vaccination against the sexually transmitted human papillomavirus (HPV) at her school in Coventry, central England, as part of a national immunization program. She later died in a hospital.

"The incident happened shortly after the girl had received her HPV vaccine in the school," Dr. Caron Grainger, joint director for Public Health for NHS (National Health Service) Coventry and Coventry City Council, said in a statement.

"No link can be made between the death and the vaccine until all the facts are known and a post mortem takes place," Grainger said. "We are conducting an urgent and full investigation into the events surrounding this tragedy."

Glaxo said it was working with the Department of Health and MHRA (Medicines and Healthcare products Regulatory Agency) to better understand the case.

"At this stage the exact cause of this tragic death is unknown," Glaxo medical director Dr. Pim Kon said in a statement.

"As a precautionary measure, the batch of vaccine involved has been quarantined until the situation is fully understood," Kon added.

News of the death comes on the eve of a possible decision by U.S. health regulators on whether to approve Cervarix for sale in the United States. However, the U.S. Food and Drug Administration often lets its expected action dates pass without a decision, or announces a delay.

A small number of other girls at the school reported mild symptoms such as dizziness and nausea but were not admitted to a hospital, health officials said.

GlaxoSmithKline, based in Brentford, Middlesex, said more than 1.4 million doses of Cervarix had been given as part of the national immunization program.

It said adverse reactions reported so far had related to signs and symptoms of recognized side effects, or were due to the injection and not the vaccine itself.

Cervarix is administered in three separate shots over six months.

Should it gain U.S. approval it would compete with Merck & Co's Gardasil, which has been in the market in the United States since 2006 and had sales of $268 million in the second quarter.

Date created : 2009-09-29

COMMENT(S)